- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
NCI CANCERLIT® Search: Diagnosis-Histopathology-Pathogenesis of Bladder Cancer - June 2002
National Cancer Institute®
Last Modified: June 1, 2002
- Primary cancer of the urinary bladder: CT evaluation of the T parameter with different techniques.
- Validation of a multicolor interphase fluorescence in situ hybridization assay for detection of transitional cell carcinoma on fresh and archival
- Bladder cancer detection with urinary survivin, an inhibitor of apoptosis.
- [Suspected bladder carcinoma. New rapid test with high sensitivity]
- Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer.
- p53 codon 72 polymorphism and its association with bladder cancer.
- New diagnostic and prognostic tools in bladder cancer.
- Accurate pathological staging of urothelial neoplasms requires better cystoscopic sampling.
- Brain metastases from bladder carcinoma: presentation, treatment and survival.
- [The value of using urinary red cell volume distribution curve of patients with positive urinary occult blood detected in a mass
- AFUD publicizes risks of cigarette smoking.
- Coffee and tea consumption and cancers of the bladder, colon and rectum.
- Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy.
- Re: pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy.
- Comparison of the bladder tumour antigen test with photodynamic diagnosis in patients with pathologically confirmed recurrent
- Hypericin-based fluorescence diagnosis of bladder carcinoma.
- [The significance of "atypical metaplasia" in the follow-up of patients operated for bladder cancer]
- [Second resection in patients with Ta-T1 bladder tumors]
Table of Contents
1
UI - 11441560
AU - Caterino M; Giunta S; Finocchi V; Giglio L; Mainiero G; Carpanese L;
TI -
Crecco M
Primary cancer of the urinary bladder: CT evaluation of the T parameter
with different techniques.
SO - Abdom Imaging 2001 Jul-Aug;26(4):433-8
AD - Department of Radiology, Cancer Institute, Regina Elena, Rome, Italy.
The evaluation of mural invasion (T) in primary urinary bladder
carcinoma is important in the planning of an appropriate surgical or
radiochemotherapeutic strategy. Previous investigators using computed
tomography (CT) have evaluated the bladder filled with urine, urine
opacified with iodinated contrast material, or air insufflation. The
purpose of this trial was to establish which of these three techniques
was the most accurate by comparing data obtained in postoperative
staging (pT). Sixty-five patients with primary bladder cancer were
enrolled, all of whom were studied by spiral CT with these three
techniques. Patients were assigned to four stage groups: Ta-T1, T2-T3a,
T3b, and T4. The results demonstrated total accuracies of 95% for the
air-insufflated bladder, 90.5% for opacified urine, and 87% for
noncontrast studies. In conclusion, the air-insufflated bladder is the
more accurate technique in the evaluation of the T parameter in primary
bladder cancer, especially in the first and third stage groups.
2
UI - 11777271
AU - Skacel M; Pettay JD; Tsiftsakis EK; Procop GW; Biscotti CV; Tubbs RR
TI -
Validation of a multicolor interphase fluorescence in situ hybridization
assay for detection of transitional cell carcinoma on fresh and archival
thin-layer, liquid-based cytology slides.
SO - Anal Quant Cytol Histol 2001 Dec;23(6):381-7
AD - Department of Anatomic Pathology, Cleveland Clinic Foundation, Ohio
44195, USA. mskacel@pol.net
OBJECTIVE: To evaluate the feasibility of performing multicolor
interphase fluorescence in situ hybridization (FISH) on ThinPrep slides
of transitional cell carcinoma (TCC). STUDY DESIGN: Slides from 20
voided urine specimens were prepared by the ThinPrep technique (Cytyc,
Boxborough, Massachusetts, U.S.A.), pretreated using a pretreatment kit
and subjected to hybridization with the multicolor FISH probe UroVysion
(Vysis, Downers Grove, Illinois, U.S.A.). Archival slides were placed in
xylene, destained in alcohol and washed prior to pretreatment. Urines
from patients with cytology-positive, biopsy-proven grade 1 (n = 5), 2
(n = 7) and 3 (n = 5) TCC and negative cytology and biopsy (n = 3) were
selected. Freshly prepared (n = 10) and archival (n = 10) slides were
used. RESULTS: All carcinoma cases were FISH positive (> 5 cells with
complex abnormalities of > or = 2 studied chromosomes per slide). None
of the normal samples were aneusomic. Gain of chromosomes 3, 7 and 17
constituted the majority of positive cases. Proper destaining and slight
decrease in stringency wash conditions enabled reliable detection of
signals in archival cases. CONCLUSION: Routine ThinPrep slides can be
used for multicolor interphase FISH analysis of urine cytology
specimens. Archival slides provide the opportunity to analyze by FISH
the nature of atypical cells identified by cytology. This revised method
allows FISH technology more accessibility for routine use in cytology
laboratories.
3
UI - 11815300
AU - Sharp JD; Hausladen DA; Maher MG; Wheeler MA; Altieri DC; Weiss RM
TI -
Bladder cancer detection with urinary survivin, an inhibitor of
apoptosis.
SO - Front Biosci 2002 Feb 1;7():e36-41
AD - Department of Surgery (Section of Urology), Yale University School of
Medicine, New Haven, Connecticut 06520, USA.
The current "gold standard" for the diagnosis of bladder cancer is
cystoscopy and urine cytology. Cystoscopy, a naked eye assessment of the
bladder, is invasive, uncomfortable and costly while cytology has high
specificity but low sensitivity (40-60%) particularly for low-grade
lesions. Therefore, there is a need for a molecular tumor marker assay
that is simple to perform and sensitive, particularly for low-grade
lesions. By looking to the pathophysiology of bladder cancer, we
identified survivin, an inhibitor of apoptosis that is not generally
expressed in fully differentiated adult tissue and is highly expressed
in bladder cancer. Survivin is detected in whole urine of patients with
TCC using a simple antibody based test. The sensitivity of survivin
testing for new or recurrent bladder cancer is 100% while the
specificity for other neoplastic and non-neoplastic genitourinary
disease is 95%. The high sensitivity of this simple, noninvasive test is
well suited to bladder cancer, a disease with high rates of recurrence.
4
UI - 11928276
AU - Anonymous
TI -
[Suspected bladder carcinoma. New rapid test with high sensitivity]
SO - MMW Fortschr Med 2002 Mar 7;144(10):65
5
UI - 11857492
AU - Davies BR; O'Donnell M; Durkan GC; Rudland PS; Barraclough R; Neal DE;
TI -
Mellon JK
Expression of S100A4 protein is associated with metastasis and reduced
survival in human bladder cancer.
SO - J Pathol 2002 Mar;196(3):292-9
AD - Department of Surgery, The Medical School, University of Newcastle,
Newcastle-Upon-Tyne NE2 4HH, UK. B.R.Davies@ncl.ac.uk
The calcium-binding protein S100A4 induces the metastatic phenotype in
rodent models of breast cancer and its expression correlates strongly
with reduced survival in human breast cancer. The expression of S100A4
in normal bladders and 101 bladder tumours has been studied using
immunocytochemistry. Moderate or strong expression of S100A4 was found
in 28% of the tumours, whilst the remaining tumours and normal
urothelium either failed to stain or showed weak staining. S100A4
staining was more frequently observed in invasive bladder tumours than
in non-invasive tumours (p<0.05). In invasive tumours, S100A4 staining
was usually strongest in invasive regions and single infiltrating cells.
Statistically significant associations were found between S100A4
expression and metastasis (p=0.0003) and reduced survival (p<0.0001). It
is concluded that S100A4 expression may play an important role in
bladder cancer and may identify a subgroup of patients at increased risk
of metastasis who should be considered for adjuvant systemic therapy.
Copyright 2002 John Wiley & Sons, Ltd.
6
UI - 11888672
AU - Soulitzis N; Sourvinos G; Dokianakis DN; Spandidos DA
TI -
p53 codon 72 polymorphism and its association with bladder cancer.
SO - Cancer Lett 2002 May 28;179(2):175-83
AD - Laboratory of Virology, Medical School, University of Crete, P.O. Box
1393, Heraklion, Crete, Greece.
p53 codon 72 Arg homozygosity has been associated with increased risk of
developing cervical cancer. This association has been tested in various
human cancers with controversial results. In the present study we
investigated the impact of this polymorphism in a population-based
case-control study of bladder cancer. Using allele-specific polymerase
chain reaction to detect the p53 codon 72 polymorphism, we tested
peripheral blood samples from 50 patients with bladder cancer and 99
healthy individuals of similar age and from the same geographical
region. Tumor specimens from all bladder cancer patients were examined
for the presence of human papilloma virus (HPV). The distribution of p53
alleles in bladder cancer patients and in controls was statistically
significant (P<0.002; odds ratio, 2.67; 95% confidence interval,
1.38-5.20), and homozygosity for arginine at residue 72 was associated
with an increased risk for bladder cancer (P<0.00002; odds ratio, 4.69;
95% confidence interval, 2.13-10.41). The presence of HPV was found in
six of the 50 patients (12%). This is the first study correlating p53
codon 72 polymorphism with bladder cancer. Our results provide evidence
that this p53 polymorphism is implicated in bladder carcinogenesis and
that individuals harboring the Arg/Arg genotype have an increased risk
of developing bladder cancer.
7
UI - 11953681
AU - Tiguert R; Fradet Y
TI -
New diagnostic and prognostic tools in bladder cancer.
SO - Curr Opin Urol 2002 May;12(3):239-43
AD - Laval University Cancer Research Center, CHUQ l'Hotel-Dieu de Quebec,
Quebec, Canada.
Many efforts have been made to increase the detection rates and to
predict the outcome of bladder cancer. Although to date cystoscopy
remains the gold standard method for the detection of new or recurrent
bladder cancer, its limitations were emphasized by the results of
studies using fluorescence endoscopy that showed an increased detection
rate and decreased recurrence after tumor resection. Urine cytology has
high specificity and is used routinely as an adjunct to cystoscopy to
detect invisible tumors. However, to improve on the low sensitivity of
urine cytology, a number of marker tests have been developed. Optimal
diagnostic accuracy appears to result from the synergistic combination
of cytological markers with urine cytology. The evaluation of new and
previously reported markers remains a very active field, but is still
limited to inconclusive studies. Tissue and DNA microarrays represent a
technological step forward for the analysis of a large number of markers
and cohorts of patients that will be required definitively to establish
the clinical utility of prognostic tests.
8
UI - 11992046
AU - Maruniak NA; Takezawa K; Murphy WM
TI -
Accurate pathological staging of urothelial neoplasms requires better
cystoscopic sampling.
SO - J Urol 2002 Jun;167(6):2404-7
AD - Department of Pathology, Immunology and Laboratory Medicine, University
of Florida College of Medicine, Gainesville, Florida, USA.
PURPOSE: The frequency with which muscularis propria was sampled by
urologists and the sources of interpretive discrepancies among
pathologists were studied in a community practice setting. MATERIALS AND
METHODS: A total of 217 consecutive cases of urothelial neoplasm were
independently reviewed by 3 pathologists. The presence or absence of
muscularis propria as well as interpretive discrepancies were recorded.
RESULTS: Despite clinical emphasis on accurate pathological staging
portions of muscularis propria were absent from samples of
histologically documented urothelial neoplasms in up to 51% of cases.
Failure to obtain muscularis propria varied widely among urologists but
was most often associated with cases of low grade papillary neoplasms,
in which invasion is less likely. Muscularis propria was usually present
in cases of noninvasive carcinoma in situ but this may have represented
inadvertent sampling of structures in close proximity. The incidence of
interpretive discrepancies among pathologists who are required to assess
the status of muscularis propria was significant (24%). Almost all
problems were related to artifacts and most may have been avoided if
careful attention had been given to specimen sampling and processing.
CONCLUSIONS: The well documented tendency toward cystoscopic under
staging has not necessarily resulted in a high incidence of muscularis
propria in bladder cases of urothelial neoplasms. Even when muscle may
have been sampled, artifacts that were often due to thermocoagulation
hampered accurate pathological staging.
9
UI - 11992049
AU - Mahmoud-Ahmed AS; Suh JH; Kupelian PA; Klein EA; Peereboom DM; Dreicer
TI -
R; Barnett GH
Brain metastases from bladder carcinoma: presentation, treatment and
survival.
SO - J Urol 2002 Jun;167(6):2419-22
AD - Department of Radiation Oncology, Brain Tumor Institute, Taussig Cancer
Center, 9500 Euclid Avenue, Cleveland Clinic Foundation, Cleveland, OH
44195, USA.
PURPOSE: We report the presentation of brain metastases from bladder
carcinoma. We investigated the role of whole brain radiation therapy for
were treated at our institution. We reviewed patient and tumor
characteristics at the time of the primary diagnosis and the brain
metastasis diagnosis. We analyzed treatment results in regard to
survival and local metastasis control. RESULTS: Brain metastases from
bladder carcinoma were commonly accompanied by uncontrolled systemic
metastases. Multiple brain lesions developed in 14 of the 16 patients.
Of the 16 patients 14 received radiation therapy with or without
surgery, 1 was treated surgically and 1 did not receive any treatment.
The 11 patients treated with whole brain radiation therapy had a median
survival of only 2 months (range 0.5 to 11). A patient who received
stereotactic radiosurgery survived 12 months after the brain metastasis
diagnosis and 2 treated with radiation therapy after surgery survived
12.75 and 2.75 months, respectively (median 7.75). The patient treated
with surgery alone survived 1.25 months after the brain metastasis
diagnosis and 1 who received no treatment survived 1.75 months. Patients
with multiple brain metastases had shorter survival than those with a
single metastasis. CONCLUSIONS: Overall survival after brain metastasis
development in patients with bladder carcinoma was poor. Although the
number of patients in this study was small, results indicate that
radiation therapy alone is inadequate treatment. Therefore, when
possible, we advocate more effective treatment by combining radiation
therapy with other treatment modalities, as recommended in ongoing
clinical trials.
10
UI - 12056036
AU - Furuya S; Ogura H; Shimamura S; Itoh N; Tsukamoto T
TI -
[The value of using urinary red cell volume distribution curve of
patients with positive urinary occult blood detected in a mass
examination]
SO - Nippon Hinyokika Gakkai Zasshi 2002 May;93(4):525-31
AD - Department of Urology, Furuya Hospital.
PURPOSE: We investigated the usefulness of the urinary red blood cell
volume distribution curve (RVDC) for screening patients who are positive
for asymptomatic urinary occult blood on mass examination. SUBJECTS AND
METHODS: The subjects were 200 individuals over 40 years old (44 men
with a median age of 53.4 years and 156 women with a median age of 57.2
years) who were positive for urinary occult blood on mass examination
into three groups based on the pattern of their RVDC. Group NG showed a
nonglomerular pattern, group M showed a mixed pattern, and group G
showed a glomerular pattern. The urological examinations performed
included DIP, ultrasound of the kidney and urinary bladder and
urethrocystoscopy. To investigate the prognosis, a questionnaire was
the state of their disease during the period since the initial
examination. RESULTS: Group G consisted of 192 patients, or almost all
of the subjects (96%). There were five patients (2.5%) who had serious
urological diseases, including two with bladder cancer, and all were
found in Groups NG and M. During the period from initial examination
until the prognosis survey (mean of 5.7 year), one patient in group G
developed both bladder and ureteral cancer. The CVDC showed a mixed
pattern when this patient was discovered. CONCLUSION: RVDC was useful
for screening patients who were found to be positive for urinary occult
blood on mass examination. When the RVDC shows a non-glomerular or mixed
pattern, detailed urological examination including endoscopy is
necessary.
11
UI - 11998283
AU - Anonymous
TI -
AFUD publicizes risks of cigarette smoking.
SO - Urol Nurs 2001 Apr;21(2):132
12
UI - 11984131
AU - Woolcott CG; King WD; Marrett LD
TI -
Coffee and tea consumption and cancers of the bladder, colon and rectum.
SO - Eur J Cancer Prev 2002 Apr;11(2):137-45
AD - Department of Community Health Sciences, University of Calgary, 3330
Hospital Drive NW, Calgary, AB T2N 4N1, Canada.
Coffee has been observed to be associated weakly or not at all with
bladder cancer risk, inversely with colon cancer risk, and
inconsistently with rectal cancer risk. The association between these
cancers and consumption of coffee and tea was examined in a single
case-control study conducted in Ontario, Canada from 1992 to 1994. A
questionnaire was filled out by 927 bladder cancer cases, 991 colon
cancer cases, 875 rectal cancer cases, and 2118 population controls.
Although bladder cancer risk was not associated with coffee or tea, risk
estimates associated with coffee among subjects who had never smoked
were non-significantly increased. Colon cancer risk was inversely
associated with coffee. Relative to those drinking less than 1 cup of
coffee per day, the odds ratios (OR) for those drinking 1-2 cups was 0.9
(95% CI 0.8-1.1), for those drinking 3-4 cups was 0.8 (95% CI 0.7-1.0),
and for those drinking 5 or more cups was 0.7 (95% CI 0.5-0.9); these
ORs decreased linearly (P = 0.008). The reduced risk estimates were more
pronounced with cancer of the proximal colon than the distal colon.
Rectal cancer risk was not associated with either coffee or tea. Coffee
consumption was observed to have a different relationship for each of
the cancer sites and tea consumption was not related to any cancer site.
13
UI - 11435814
AU - Mills RD; Turner WH; Fleischmann A; Markwalder R; Thalmann GN; Studer UE
TI -
Pelvic lymph node metastases from bladder cancer: outcome in 83 patients
after radical cystectomy and pelvic lymphadenectomy.
SO - J Urol 2001 Jul;166(1):19-23
AD - Department of Urology and Institutes of Pathology, University of Berne,
Berne, Switzerland.
PURPOSE: We evaluate the outcome in patients with node positive bladder
cancer with particular reference to the effect of individual
characteristics of positive nodes on survival after meticulous pelvic
lymphadenectomy at cystectomy. MATERIALS AND METHODS: This prospective
analysis contains 452 cases of bladder cancer staged preoperatively as
N0M0, managed with pelvic lymphadenectomy and cystectomy between 1984
and 1997. A total of 83 (18%) patients with histologically confirmed
node positive disease are included in our study. RESULTS: The median
overall survival of patients with positive nodes was 20 months. Median
5-year survival was 29%. Patients who survived were found with positive
nodes at each site in the pelvis. The median survival of 57 patients
with less than 5 positive nodes was 27 months, compared with 15 months
for 26 with 5 nodes or more (log-rank test p = 0.0027). Median survival
of 26 patients with no lymph node capsule perforation was 93 months,
compared with 16 months for 57 with capsule perforation (p = 0.0004).
The median survival of 18 patients with a maximum diameter of lymph node
metastasis up to 0.5 cm. was 64 months, compared with 16 months for 65
with nodal metastasis greater than 0.5 cm. (p = 0.024). Contralateral
positive nodes were found in 16 of 39 (41%) patients with unilateral
bladder cancer. CONCLUSIONS: Long-term survival is possible with node
positive bladder cancer. Those patients with few as well as smaller and,
therefore, unsuspected nodal metastases, and those without lymph node
capsule perforation have the best results after removal of pelvic
metastatic nodal disease. Because patients who survive may be found
regardless of the site of pelvic nodal metastases, meticulous bilateral
pelvic lymphadenectomy is warranted in all patients at the time of
attempted curative cystectomy for bladder cancer, particularly if there
is no clinical evidence of nodal involvement.
14
UI - 11792943
AU - Neulander EZ
TI -
Re: pelvic lymph node metastases from bladder cancer: outcome in 83
patients after radical cystectomy and pelvic lymphadenectomy.
SO - J Urol 2002 Feb;167(2 Pt 1):651
15
UI - 11966640
AU - Lipinski M; Jeromin L
TI -
Comparison of the bladder tumour antigen test with photodynamic
diagnosis in patients with pathologically confirmed recurrent
superficial urinary bladder tumours.
SO - BJU Int 2002 May;89(7):757-9
AD - Clinic of Urology, Medical University of Lodz, Pabianicka 62, 93-513
Lodz, Poland. miklipa@poczta.onet.pl
OBJECTIVE: To verify the sensitivity of the bladder tumour antigen
(BTAstat, Bard Urological, Covington, GA) test against the sensitive
procedure of photodynamic diagnosis (PDD), in which 5-aminolaevulinic
acid (5-ALA, a precursor of fluorescent porphyrins) is absorbed by the
tumour and detected by ultraviolet cystoscopy, in the early diagnosis of
urinary bladder tumours. PATIENTS AND METHODS: Forty-three patients (31
men and 12 women, age range 21-87 years) were assessed after
transurethral resection of their bladder tumour using the BTAstat test
and PDD. Sixty-nine biopsies from suspect areas of bladder mucosa were
taken during cystoscopy under ultraviolet light and all suspect lesions
electrocoagulated. RESULTS: Thirty-five patients (81%) had a positive
BTAstat test; in these patients PDD detected malignant lesions (17
Ta1G1-2, two T1G2, two T1G3 and 14 Tis). In eight patients (19%) the
BTAstat was negative but PDD detected three malignant lesions (two Tis
and one TaG1). CONCLUSIONS: PDD is valuable for detecting bladder
malignancy and can identify small lesions not detected by the BTAstat
test.
16
UI - 11966641
AU - D'Hallewin MA; Kamuhabwa AR; Roskams T; De Witte PA; Baert L
TI -
Hypericin-based fluorescence diagnosis of bladder carcinoma.
SO - BJU Int 2002 May;89(7):760-3
AD - Department of Urology, UZ Gasthuisberg, Herestraat 49, B-3000 Leuven,
Belgium. marie-ange.dhallewin@uz.kuleuven.ac.be
OBJECTIVE: To determine the use of hypericin instillation for the
fluorescent detection of papillary bladder cancer and carcinoma in situ.
PATIENTS AND METHODS: Eighty-seven patients with papillary bladder
cancer and/or carcinoma in situ received instillations with 40 mL of an
8 micromol/L hypericin solution for at least 2 h. Fluorescent excitation
with blue light was effective for up to 16 h, and biopsies were examined
by fluorescence microscopy. RESULTS: There were no side-effects
reported, no photobleaching and all papillary lesions fluoresced red.
The sensitivity and specificity for detecting carcinoma in situ was 94%
and 95%, respectively. An interval of 4 months is recommended after BCG
instillations before using this test. Fluorescence microscopy showed
that hypericin was selectively localized in the epithelium. CONCLUSIONS:
Hypericin-induced fluorescence has a high sensitivity and specificity
for detecting bladder cancer. After 4 months there are few
false-positive results in patients treated with BCG.
17
UI - 11455318
AU - Giovagnoli MR; Rocchi M; Grillo L; Vecchione A
TI -
[The significance of "atypical metaplasia" in the follow-up of patients
operated for bladder cancer]
SO - Minerva Urol Nefrol 2001 Jun;53(2):93-7
AD - II Facolta di Medicina e Chirurgia, Scuola di Specializzazione in
Oncologia II, Universita degli Studi La Sapienza, Rome.
mariarosaria.giovagnoli@uniromal.it
BACKGROUND: The aim of this study was to evaluate the clinical
usefulness of urinary cytology in the follow-up of patients who
under-went surgery for bladder cancer. Particularly, the positive
predictive value of urinary cytology and time elapsed between a positive
test and the diagnosis of a cystoscopically confirmed bladder tumor are
analyzed. METHODS: This study was carried out at the Cytological
Laboratory Department of Experimental Medicine and Pathology, University
La Sapienza, Rome. Among 230 cases studied since 1996, 30 male patients
over 50 were examined (25 with a previous bladder cancer and 5 with a
previous prostate cancer) with long time follow-up, who underwent more
than two cytological examinations on voided urine (2-12) at pre-fixed
intervals. RESULTS: Nine (30%) of the patients suffered from recurrent
disease. The cytological examinations was positive in 8 out of the 9
positive cases and negative in 17 out of the 21 negative cases. Absence
of disease was confirmed in all the latter cases both by cystoscopic
examination and clinical follow-up. One negative case showed clearly
malignant cells in more than one specimen taken at different time
intervals. This patient is actually under strict control. In 5 cases
atypical metaplasia was present in the cytological specimen. In two of
those cases cystoscopic examination 5 and 8 months later confirmed
progressive disease. In the other three cases cystoscopy showed no
evidence of disease. Two of the patients are well and alive after 2 and
14 months respectively. One is dead of prostatic cancer. CONCLUSIONS:
Considering the cases of atypical metaplasi as positive the cytological
examinations showed 100% sensibility, 81% specificity, a predictive
negative value of 1 and a predictive positive value of 0.66.
18
UI - 11692797
AU - Rodriguez-Rubio Cortadellas FI; Garrido Insua S; Rivas Aguayo D; Hens
TI -
Perez A; Bachiller Burgos J; Beltran Aguilar V; Varo Solis C; Sanchez
Bernal C; Juarez Soto A; Gonzalez Moreno D
[Second resection in patients with Ta-T1 bladder tumors]
SO - Actas Urol Esp 2001 Sep;25(8):553-8
AD - Servicio de Urologia, Hospital Universitario de Puerto Real, Cadiz.
OBJECTIVES: To study the incidence of "residual/recurrence" tumor after
a second bladder resection (2nd TUR). METHODS: 40 patients with new or
recurrent superficial bladder tumor underwent repeat transurethral
resection within 3 months after the initial resection. 37 patients were
staged as Ta-T1. We study the incidence of tumor after the 2nd TUR both
macroscopically detected or included in the bladder scar. We also study
the influence of possible factors as the time between both resections,
stage, grade, number of tumor size, localization in the bladder, primary
or recurrent tumor and tumor pattern. RESULTS: After the 2nd TUR we
found tumor in 14 of 37 (37.8%) Ta-T1 bladder tumors. Among the 14
tumors, 10 (71.5%) were macroscopically visible tumors and 4 cases the
tumor were found after resection of the bladder scar of the first
resection. We did not find relation between the presence of tumor in the
2nd TUR and any of the variables. CONCLUSIONS: After a TUR of
superficial bladder tumor the complete removal of tumor is not always
achieved. The early 3 months cystoscopy may not find residual tumor.
Although we have found tumor in 37.8% in the 2a TUR we can not recommend
routine 2nd TUR in superficial bladder cancer.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
